In Vitro and In Vivo Evaluation of 28DAP010, a Novel Diamidine for Treatment of Second-Stage African Sleeping Sickness by Wenzler, Tanja et al.
In Vitro and In Vivo Evaluation of 28DAP010, a Novel Diamidine for
Treatment of Second-Stage African Sleeping Sickness
Tanja Wenzler,a,b Sihyung Yang,c Donald A. Patrick,d Olivier Braissant,b,e Mohamed A. Ismail,f Richard R. Tidwell,d David W. Boykin,f
Michael Zhuo Wang,c Reto Bruna,b
Medical Parasitology & Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerlanda; University of Basel, Basel, Switzerlandb; Department of
Pharmaceutical Chemistry, School of Pharmacy, The University of Kansas, Lawrence, Kansas, USAc; Department of Pathology and Laboratory Medicine, School of
Medicine, University of North Carolina, Chapel Hill, North Carolina, USAd; Department of Urology, University Hospital of Basel, Basel, Switzerlande; Department of
Chemistry, Georgia State University, Atlanta, Georgia, USAf
African sleeping sickness is a neglected tropical disease transmitted by tsetse flies. New and better drugs are still needed espe-
cially for its second stage, which is fatal if untreated. 28DAP010, a dipyridylbenzene analogue of DB829, is the second simple
diamidine found to cure mice with central nervous system infections by a parenteral route of administration. 28DAP010 showed
efficacy similar to that of DB829 in dose-response studies in mouse models of first- and second-stage African sleeping sickness.
The in vitro time to kill, determined by microcalorimetry, and the parasite clearance time in mice were shorter for 28DAP010
than for DB829. No cross-resistance was observed between 28DAP010 and pentamidine on the tested Trypanosoma brucei gam-
biense isolates from melarsoprol-refractory patients. 28DAP010 is the second promising preclinical candidate among the diami-
dines for the treatment of second-stage African sleeping sickness.
African sleeping sickness, also known as human Africantrypanosomiasis (HAT), is a tropical disease that threatens
millions of people living in sub-Saharan Africa (1). It is caused by
two subspecies of the single-celled parasite Trypanosoma brucei,
Trypanosoma brucei gambiense and Trypanosoma brucei rhod-
esiense. The protozoans are transmitted by the bite of infected
tsetse flies. The disease is fatal without effective treatment. The
burden of the disease has been reduced to some extent by in-
creased control interventions, but the disease is still one of the
most neglected tropical diseases, and it is estimated by the WHO
that there are still 25,000 to 30,000 infected patients (2, 3).
HAT progresses in two stages. In the first stage, the parasites
reside in the blood and the lymphatic system. In the second stage,
the parasites cross the blood-brain barrier (BBB) and spread the
infection to the central nervous system (CNS), leading to neuro-
logical and psychiatric disorders, including irregular and frag-
mented sleeping patterns, behavioral changes, motor weakness,
coma, and ultimately death (4).
Patients can be cured only by effective and safe drugs. Vaccines
are not available and are unlikely to be developed in the near
future, and self-healing through the body’s own immune system is
also not possible due to antigenic variation of the surface glyco-
proteins of the parasites (5). The drugs currently available have
serious disadvantages such as adverse effects, limited efficacy,
complicated treatment schedules, and the need for parenteral ad-
ministration. New drugs are therefore needed, especially for the
second stage of the disease.
In the search for new drugs, aromatic diamidines are seen as
promising candidates for use against HAT. These compounds are
known to have a broad spectrum of antiprotozoal activities (6).
Pentamidine has been in use since the 1940s for first-stage T. b.
gambiense HAT and against leishmaniasis and Pneumocystis ji-
rovecii pneumonia (7). Diminazene (8) and isometamidium (a
monoamidine) are used to treat animal trypanosomiasis. There-
fore, considerable effort has been put into the synthesis and inves-
tigation of novel aromatic diamidines with improved properties
for use against HAT.
One problem with diamidines is that they are protonated at
physiological pH and therefore do not easily cross the gastrointes-
tinal tract and the BBB by diffusion. Their cationic nature was
therefore believed to reduce their potential for use as oral drugs
and to reduce their efficacy against second-stage HAT by any
route of administration; therefore, much effort went into the de-
sign of prodrugs (6, 9). Prodrugs are inactive against trypano-
somes in vitro but can be metabolized to the active diamidine
molecules by host enzymes upon administration in vivo (10–12),
thus serving as potentially orally active drugs. The prodrug ap-
proach worked well with regard to oral bioavailability in animal
models (9, 13, 14) as well as in humans, in whom the prodrug
DB289 (pafuramidine maleate) underwent clinical trials as the
first oral drug for treatment of first-stage HAT patients (15, 16).
Several other prodrugs have been tested in the second-stage
mouse model, but few of them were able to cure CNS infections in
mice (14, 17).
During a series of tests in our laboratory, we discovered that the
diamidine DB829 was intrinsically active in second-stage animal
models (14, 18). This was unexpected, as simple diamidines (ami-
dines without substituents on either nitrogen atom) are thought
to be unable to cross the BBB by diffusion due to their cationic
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nature. For many years, DB829 remained the only diamidine that
showed high CNS activity in vivo (14, 19).
Recently, we found that 28DAP010 (also known as CPD0905)
and its close analogues 19DAP025 and 27DAP060 were highly
active in vitro against T. b. rhodesiense and were curative in the
stringent T. b. rhodesiense STIB900 first-stage mouse model at the
low dose of 4  5 mg/kg of body weight (i.e., daily dose of 5 mg/kg
given on 4 consecutive days) or as a single dose of 10 mg/kg by an
intraperitoneal (i.p.) route of administration (20). In this paper,
we present more data from our investigations of this new novel
diamidine with high CNS activity in vivo, 28DAP010, and its an-
alogues 19DAP025 and 27DAP060. We performed a full dose-
response experiment in the STIB900 acute-stage mouse model to
determine the minimal curative dose for the three compounds
and evaluated their CNS activity in the GVR35 CNS mouse model.
As 28DAP010 showed better efficacy than the analogues, we car-
ried out a detailed biological characterization of this compound.
We collected in vitro data on different T. brucei strains and sub-
species, with a particular emphasis on trypanocidal activity on T.
b. gambiense, as the majority (98%) of African sleeping sickness
patients are infected with T. b. gambiense (2). Additionally, we
assessed the time to kill of 28DAP010 in vitro using microcalorim-
etry, a new method to measure drug activity on a real-time basis
(21). This was important, because aromatic diamidines typically
kill the trypanosomes rather slowly, with a time to kill of about 24
to 48 h after treatment (22). Among the diamidines, DB829 was
one of the slowest-acting compounds, with a time to kill of 48 h
(23). After having analyzed the pharmacokinetic properties of
28DAP010 in mice at a curative single dose, we assessed the para-
site clearance time at an identical dose in mice infected with T. b.
rhodesiense and T. b. gambiense strains.
MATERIALS AND METHODS
Materials. Pentamidine isethionate was purchased from Sigma-Aldrich
(St. Louis, MO). Syntheses of 28DAP010 (CPD-0905) (20), 19DAP025
(20), 27DAP060 (20), DB829 (24), DB1244 (20) and deuterium-labeled
DB75 (DB75-d8; deuterated phenyl rings; internal standard) (25), all iso-
lated as their hydrochloride salts, have been previously reported.
Antitrypanosomal activities of 28DAP010 and pentamidine in vitro.
(i) Preparation of compounds. Compounds were dissolved in 100% di-
methyl sulfoxide (DMSO) and finally diluted in culture medium prior to
the in vitro assay. The DMSO concentration never exceeded 1% in the in
vitro alamarBlue assays at the highest drug concentration. For microcalo-
rimetry assays, the DMSO concentration was kept at 0.1% in all samples.
(ii) Parasites. The T. brucei strains used in this study are described in
Table 1.
(iii) In vitro growth inhibition assays using T. brucei subspecies.
The 50% inhibitory concentrations (IC50s) were determined using the
alamarBlue assay as described by Räz et al. (26), with a 3-day drug expo-
sure and minor modifications as described previously (23). Assays were
carried out at least three times independently and each time in duplicate.
The IC50s are the means of the independent assays. Coefficients of varia-
tion were less than 50%. Different culture and assay media were used for
T. b. gambiense and T. b. rhodesiense, as previously described by Wenzler et
al. (23).
(iv) Microcalorimetry studies using T. brucei subspecies. In vitro
time of drug action was monitored using isothermal microcalorimetry.
With this method, the time of drug action on a parasite population can be
determined on a real-time basis (21, 23). The strain STIB900 was used as
a representative for T. b. rhodesiense and STIB930 (and sometimes addi-
tionally ITMAP141267) for T. b. gambiense.
For experiments with continuous drug exposure, bloodstream try-
panosomes (2 ml at 5  104/ml per ampoule) were spiked with different
concentrations of 28DAP010, with a final DMSO concentration of 0.1%
(vol/vol). Negative controls contained culture medium only. The heat
flow was continuously measured (1 reading/second) at 37°C in the iso-
thermal microcalorimetry instrument (thermal activity monitor, model
249 TAM III). Each experiment with continuous drug exposure was set up
in triplicate and carried out a total of 3 times (21).
(v) Inoculum studies. For studies of the drug effect on different par-
asite densities in the inoculum, the parasite density was reduced to 1 
104/ml of bloodstream trypanosomes and supplemented with 28DAP010
at the desired concentrations. Inhibition of growth and viability was com-
pared with that in the samples containing the standard inoculum of 5 
104/ml of bloodstream trypanosomes and the same drug concentrations
(23). Each experiment was set up in triplicate and repeated once.
(vi) Drug wash-out experiments. For the 24-h exposure experiment,
trypanosomes (T. b. rhodesiense strain STIB900 and T. b. gambiense strain
STIB930) were incubated with 28DAP010 for 24 h at 37°C and then
washed twice to remove the compound. Subsequently, the washed try-
panosomes were resuspended in drug-free culture medium, transferred to
ampoules, and inserted into the isothermal microcalorimetry instrument.
The drug-free control samples (drug free, wash-out) were washed identi-
cally to the drug-containing samples. Each 24-h exposure experiment was
set up in triplicate and repeated once (23).
(vii) Analysis of microcalorimetry heat flow data. To facilitate fur-
ther calculations, the recorded data were resampled to obtain an effective
sampling frequency of 1 data point per 1.5 min, using the manufacturer’s
software (TAM assistant version v1.2.4.0), and exported to a spreadsheet.
Forty-five minutes was added to the time data to account for the prepa-
ration of the ampoules and the transfer from the bench to the calorimeter.
Resulting data were plotted as heat flow (in W) over time. Each single
curve for heat flow (in watts) over time was analyzed using the R statistical
package (27). Data were smoothed using a cubic spline (smooth.spline
function) in the R statistical software (27–30). The time to onset of drug
action was determined as the time at which a divergence between the heat
flow of the drug-free controls and the drug-containing specimens could
be observed. The time to peak was determined as the time point at which
the highest heat flow was measured for each samples. The time to kill the
parasite population was defined as the time point when the heat produc-
tion was reduced to the level of the sterile medium control (base level)
(23).The growth rate () of each culture was calculated using the heat-
over-time data (integrated heat flow data over time). For this calculation,
the Gompertz growth model was fitted over the whole curve using R
software and the Grofit package as described previously (23, 31). The
growth rate calculated based on the heat released by the metabolic activity







T. b. rhodesiense 1982 Tanzania 52
BS221, S427 T. b. brucei 1960 Uganda 42
BS221AT1 T. b. brucei 42
GVR35, S10 T. b. brucei 1966 Serengeti 53
STIB930,
STIB754
T. b. gambiense 1978 Côte d’Ivoire 54
ITMAP141267 T. b. gambiense 1960 DRC 55
130R T. b. gambiense 2005 DRC 56
40R T. b. gambiense 2005 DRC 56
45R T. b. gambiense 2005 DRC 56
349R T. b. gambiense 2006 DRC 56
DAL898R T. b. gambiense 1985 Côte d’Ivoire 52
K03048 T. b. gambiense 2003 South Sudan 57
a Strains labeled with an “R” were isolated from patients after a relapse after
melarsoprol treatment.
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in the culture is considered only as a proxy for the growth rate calculated
from the exponential growth phase by conventional approaches, since
lysis and chemical processes due to the nature of the medium might also
contribute to the overall heat signal (23, 31).
In vivo studies. (i) Efficacy and time to kill in mice. The efficacy and
time-to-kill experiments were performed at the Swiss Tropical and Public
Health Institute. Adult female NMRI (Naval Medical Research Institute)
mice were obtained from Janvier, France, or from Harlan, the Nether-
lands. They weighed between 20 and 25 g at the beginning of the study and
were housed under standard conditions with food pellets and water ad
libitum. All protocols and procedures were reviewed and approved by the
veterinary authorities of Canton Basel-Stadt, Switzerland. For experi-
ments with mice, the compounds were dissolved in DMSO and further
diluted with distilled water to a final DMSO concentration of 10% prior to
administration to the animals.
(ii) Efficacy in an acute-stage T. b. rhodesiense STIB900 mouse
model. The STIB900 acute-stage mouse model mimics the first (hemo-
lymphatic) stage of HAT. Experiments were performed as previously re-
ported (23). Briefly, four female NMRI mice per group were infected
intraperitoneally (i.p.) with 5  103 STIB900 bloodstream forms. Drug
administration (i.p.) began 3 days after infection. A control group was
infected but remained untreated. All mice were monitored for parasitemia
by microscopic examination of tail blood twice a week until day 30, fol-
lowed by once a week until 60 days after infection. The time to parasite
relapse was recorded to calculate the mean relapse time in days after in-
fection. Mice were euthanized after parasitemia relapse detection. Mice
were considered cured if they survived and were aparasitemic until day 60.
(iii) Efficacy in acute-stage T. b. gambiense mouse models. Experi-
ments were performed as previously reported (23). Briefly, four female
NMRI mice per group were immunosuppressed with 200 mg/kg of cyclo-
phosphamide (Endoxan, Baxter, Deerfield, IL) 2 days prior to infection
with 105 bloodstream forms with one of the four T. b. gambiense strains
(i.e., ITMAP141267, STIB930, 130R, or 45R). Immunosuppression with
cyclophosphamide followed every second week until the end of the exper-
iment. Drug administration (i.p.) began 3 days after infection. A control
group was infected but remained untreated. Mice were monitored for
parasitemia twice a week until day 30 and then once a week until 90 days
after infection. Mice were considered cured if they survived and were
aparasitemic until day 90.
(iv) Efficacy in a CNS stage T. b. brucei GVR35 mouse model. The
GVR35 mouse CNS model mimics the second stage of the disease. GVR35
is a less virulent strain than STIB900 and crosses the BBB of mice around
7 days after infection (32). Experiments were performed as previously
reported (14), with minor modifications. Five female NMRI mice per
experimental group were used. Each mouse was inoculated i.p. with 2 
104 bloodstream forms. The drug administration was i.p. for diamidines
and per os (p.o.) for prodrugs on five consecutive days from day 17 to 21
after infection. Some experimental groups were treated for 10 consecutive
days (day 17 to 26 after infection). A negative-control group was treated
on day 17 with a single dose of diminazene aceturate at 40 mg/kg of body
weight i.p., which is subcurative since it clears the trypanosomes only
from the hemolymphatic system and not from the CNS, leading to a
subsequent reappearance of trypanosomes in the blood (33). Parasitemia
was monitored twice a week from the time after treatment until day 50
after infection, followed by once a week until 180 days after infection.
Mice were considered cured when there was no parasitemia relapse de-
tected over the 180-day observation period. Surviving and aparasitemic
mice were euthanized on day 180.
(v) In vivo time to kill. Infection with T. b. rhodesiense and T. b.
gambiense and immunosuppression for T. b. gambiense-infected mice
were carried out as described for the efficacy experiments. In different
mouse models the parasite load varied, an observation that was also made
in the efficacy experiments. Mice were treated with a single dose of 20
mg/kg i.p. 3 days postinfection. The first microscopic examination of
blood was done 24 h after treatment, and examination was done subse-
quently twice per day until all parasites had disappeared. When micros-
copy was not sensitive enough to detect any parasites, a hematocrit buffy
coat examination was performed. The first time point at which no try-
panosomes were detected on the microscopic slide or in the buffy coat was
considered the clearance time (or time to kill) in mice. The detection limit
by buffy coat examination was 100 trypanosomes/ml of blood. Mice
were kept and further observed by tail blood examination until the end of
the experiment to verify whether the administered dose was curative in the
infected mice (23).
Pharmacokinetic studies. (i) Animals for PK studies. The pharma-
cokinetic (PK) studies were performed at the University of Kansas. Pro-
tocols for the animal studies were approved by the Institutional Animal
Care and Use Committee of the University of Kansas. Male Swiss Webster
mice (weighing 20 to 25 g) were purchased from the Charles River Labo-
ratories (O’Fallon, MO). Mice were housed in a clean room under filtered,
pathogen-free air, in a 12-h light/dark cycle, and with food pellets and
water available ad libitum. Although a different strain and sex of mice were
used in our PK studies compared to efficacy studies, we did not expect that
diamidine PK would differ significantly between different strain and sex of
mice.
(ii) Pharmacokinetics and brain exposure in mice. The single-dose
pharmacokinetics of 28DAP010 was evaluated in mice (in triplicate) after
intravenous (i.v.) and i.p. administration. 28DAP010 was dissolved in
sterile saline. The doses were 7.5 mol/kg (approximately 2.4 mg/kg) for
i.v. administration and 65 mol/kg (approximately 21 mg/kg) for i.p.
administration, which was the dose used in the in vivo time-to-kill study.
The dose volume was 5 ml/kg. No overt adverse effects were observed in
mice at these dose levels. Blood sampling occurred at 0.25, 0.5, 1, 2, 4, 6, 8,
12, 24, 48, and 72 h postdose. Additional earlier sampling times, at 0.0167
and 0.083 h, were included for the i.v. administration. Blood was collected
via the submandibular vein (0.04 ml per bleed) or heart (0.8 ml) into
lithium heparin-coated Microvette tubes (Sarstedt Inc., Newton, NC).
Terminal blood and brain samples were collected at 4, 12, and 72 h post-
dose. Plasma was obtained by centrifugation. Excised mouse brain sam-
ples were quickly rinsed with distilled water, blotted dry with tissue paper,
and weighed. All samples were stored at 20°C until further processing
for quantification by ultrahigh-performance liquid chromatography-tan-
dem mass spectrometry (UPLC-MS/MS).
(iii) Plasma and tissue binding assays. Binding of 28DAP010 to
mouse plasma and brain was evaluated by the equilibrium dialysis method
using a rapid equilibrium dialysis device (Thermo Scientific Pierce, Rock-
ford, IL) as previously described (34). Briefly, blank (untreated and unin-
fected) mouse brains were collected and homogenized in 2 volumes (vol/
wt) of water (3-fold dilution). 28DAP010 was spiked into blank plasma or
brain homogenates to yield a final drug concentration of 1 M. Spiked
plasma or brain homogenates (in triplicate) were added to the dialysis
device and dialyzed against phosphate-buffered saline (PBS) for 6 h at
37°C to reach equilibrium between the plasma/tissue compartment and
the buffer compartment. At the end of incubation, samples from the plas-
ma/tissue compartment and the buffer compartment were collected and
analyzed for total and unbound concentrations by UPLC-MS/MS. Un-
bound fractions in the mouse brain (fu, brain) were calculated by correcting
for dilution (35).
(iv) UPLC-MS/MS analysis. (a) Sample preparation. Plasma samples
(2 l) were mixed with 200 l of 7:1 (vol/vol) methanol-water containing
0.1% trifluoroacetic acid and an internal standard (1 nM DB75-d8) and
then vortex mixed for 30 s, followed by centrifugation (2,800  g) to pellet
proteins. The supernatant was transferred to a new tube and dried using a
96-well microplate evaporator (Apricot Designs Inc., Covina, CA) under
N2 at 50°C and reconstituted with 100 l of 15% methanol containing
0.1% trifluoroacetic acid.
(b) Determination of drug concentration. The reconstituted samples
(5-l injection volume) were analyzed for drug concentration using a
Waters Xevo TQ-S mass spectrometer (Foster City, CA) coupled with
a Waters Acquity UPLC I-Class system. Compounds were separated on a
Wenzler et al.
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Waters UPLC BEH C18 column (2.1 mm by 50 mm by 1.7 m) equili-
brated at 50°C. UPLC mobile phases consisted of water containing 0.1%
formic acid (solution A) and methanol containing 0.1% formic acid (so-
lution B). After a 0.15-min initial holding period at 10% solution B, mo-
bile phase composition started with 10% solution B and was increased to
80% solution B over 2.2 min with a flow rate of 0.4 ml/min. Then the
column was washed with 90% solution B for 0.5 min and was reequili-
brated with 5% solution B for 1.1 min before injection of the next sample.
The characteristic single reaction monitoring (SRM) transition for
28DAP010 and DB75-d8 were m/z 317.1¡283.1 and 313.2¡296.3, re-
spectively, under positive electrospray ionization mode. The calibration
curves for 28DAP010 ranged from 0.5 nM to 50 M. The intraday coef-
ficient of variation (CV) and accuracy were determined by measuring the
same preparation of three standards three times on the same day. At
concentrations of 5, 1,000, and 25,000 nM, the intraday CV and average
accuracy of 28DAP010 quantification were 11.2% and 103%, 5.33% and
104%, and 0.70% and 106%, respectively.
(v) Pharmacokinetic analysis. The total area under the plasma con-
centration-time curve (AUC), terminal elimination half-life (t1/2), maxi-
mum plasma drug concentration (Cmax), time to reach Cmax (Tmax), clear-
ance (CL), steady-state volume of distribution (Vss), and mean residence
time (MRT) were calculated using the trapezoidal rule-extrapolation
method and noncompartmental analysis (WinNonlin version 5.0; Phar-
sight, Mountain View, CA).
RESULTS
Acute-stage T. b. rhodesiense mouse model. 28DAP010 and its
two analogues 19DAP025 and 27DAP060 (Fig. 1) are highly active
in vitro as well as in vivo against African trypanosomes (20).
Within this study we analyzed the minimal curative dose in the
stringent STIB900 acute-stage mouse model. All three com-
pounds showed superior activity, curing all mice at 4  5 mg/kg
i.p. or at single doses of 10 mg/kg i.p. (28DAP010 and 19DAP025)
or 5 mg/kg i.p. (27DAP060) (20) (Table 2). Pentamidine cured
only 1/4 mice at 4  5 mg/kg i.p. (23). In vivo efficacies of
28DAP010 and 19DAP025 were comparable. Cure rates of 3/4 or
2/4 mice were attained at a daily dose of 5 mg/kg i.p. or 1 mg/kg
administered on 4 consecutive days. 27DAP060 was slightly more
effective than 28DAP010 and 19DAP025. With the low dose of
4  0.25 mg/kg i.p., none of the 3 compounds were able to cure
any of the mice, and the parasitemia relapses were detected already
around 4 days after the last drug administration. 28DAP010 and
its dipyridylfuran analogue DB829 showed similar efficacies in the
STIB900 acute-stage mouse model (Table 2).
CNS T. b. brucei mouse model. The high efficacies in the
acute-stage mouse model showed that the compounds merited
further testing in the GVR35 CNS mouse model. 28DAP010 was
the most potent compound among the three diamidines, curing
all infected mice at 10  20 mg/kg i.p. (Table 3). The high CNS
activity is exceptional, having been observed so far with only one
other diamidine, DB829 (14).
The two analogues of 28DAP010 —19DAP025 and
27DAP060 —were both less effective and did not achieve any
cures. Additionally, 19DAP025 was toxic and killed most of the
mice at the dosages administered. 28DAP010 was also tested at 25
mg/kg for only 5 days and was almost as potent as DB829. This is
only a slightly higher total dose than 10 mg/kg i.p. administered
for 10 days but was clearly more effective (Table 3). 28DAP010
was well tolerated in NMRI mice at 5  25 mg/kg and 10  20
mg/kg i.p., without any overt toxicity observed.
The prodrug DB1244 is a methamidoxime derivative of
28DAP010 (analogous to DB868 being the methamidoxime de-
rivative of DB829). It has been tested orally at 100 mg/kg admin-
istered on 5 consecutive days. At identical oral doses, DB1244 was
FIG 1 Chemical structures of 28DAP010, its prodrug DB1244, and its ana-
logues.
TABLE 2 In vivo antitrypanosomal activities of 28DAP010 and its analogues 19DAP010 and 27DAP060 (along with dipyridylfuran analogue
DB829) in mice with acute-stage STIB900 T. b. rhodesiense infectionsa
Dose regime (no. of
doses  mg/kg)
28DAP010 (in vitro IC50
[nM], 17 	 4)
19DAP025 (in vitro IC50
[nM], 4 	 1)
27DAP060 (in vitro IC50
[nM], 6 	 1)
DB829 (in vitro IC50 [nM],
20 	 4)
No. of mice cured/
no. infected MRD
No. of mice cured/
no. infected MRD
No. of mice cured/
no. infected MRD
No. of mice cured/
no. infected MRD
1  5 i.p. 3/4 17 2/4 17 4/4 2/4 53.5
1  10 i.p. 4/4 4/4 ND 4/4
4  0.25 i.p. 0/4 12 0/4 9.25 0/4 13 0/4 14.75
4  1 i.p. 3/4 14 2/4 19 4/4 3/4 14
4  5 i.p. 4/4 4/4 4/4 4/4
a DB1244, the methamidoxime prodrug of 28DAP010, cured 2/4 mice at 4  25 mg/kg p.o. (20). IC50s are from references 20 and 23 and are expressed as means 	 standard
deviations. No. of doses  mg/kg, one daily dose administered on consecutive days; MRD, mean relapse day; ND, not determined.






No. of mice cured/no. infected
28DAP010 19DAP025 27DAP060 DB1244
DB829 or
diminazene
5  25 i.p. 2/5, 5/6a 0/1d 4/5,b 6/6a,b
10  10 i.p. 0/5, 1/6a
10  20 i.p. 5/5 0/1d 0/4
5  100 p.o. 0/5
1  40 i.p. 0/5c
a Cure obtained in a previous experiment.
b Result for DB829.
c Result for diminazene.
d Several mice died or were euthanized due to compound toxicity.
e No. of doses  mg/kg, one daily dose administered on consecutive days.
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less potent in the CNS mouse model (no cures [Table 3]) than
DB868 (5/5 mice cured) (14).
In vitro activity against different trypanosome strains. We
analyzed the in vitro activity of 28DAP010 against different try-
panosome isolates in the alamarBlue viability assay. As most sleep-
ing sickness patients suffer from T. b. gambiense infections, we
tested 28DAP010 against several T. b. gambiense field isolates. The
strains and culture conditions were identical to those used to de-
termine the trypanocidal activity of DB829 (23), so the IC50s of
28DAP010 and DB829 can therefore directly be compared. The in
vitro IC50s of 28DAP010 were higher for all tested T. b. gambiense
isolates (IC50 
 45 to 215 nM [Fig. 2]) than for T. b. rhodesiense
strain STIB900 (IC50 
 17 nM) and T. b. brucei strain BS221
(IC50 
 25 nM). Among the T. b. gambiense strains, there was no
clear correlation between isolates from patients suffering from a
relapse after melarsoprol treatment (strains whose name includes
“R”) and reduced potency of 28DAP010 (Fig. 2), whereas pent-
amidine appeared to be less active against strains that had been
recently isolated (since 2003), which has also previously been
shown (23). 28DAP010 was more active against the four “R”
strains (130R, 349R, 40R, and DAL898R) than against the refer-
ence melarsoprol-sensitive strain STIB930. ITMAP141267 was
the oldest isolate tested in this study (isolated in 1960 from the
Democratic Republic of the Congo [DRC]), and it was the strain
most sensitive to 28DAP010 and among those most sensitive to
pentamidine (Fig. 2). However, no correlation in reduced
trypanocidal activity among T. b. gambiense strains was observed
between 28DAP010 and pentamidine (r2 
 0.019) or with the
isolates from melarsoprol-refractory patients.
We additionally studied the dependency of the P2 trans-
porter for the uptake of 28DAP010 into trypanosomes using
BS221AT1, a P2 knockout strain (IC50 
 400 nM), and its cor-
responding wild type, BS221 (IC50 
 25 nM), by comparing the
IC50s determined in the alamarBlue assay. The resistance factor
(RF) obtained with 28DAP010 on the P2 knockout strain (RF 

16) was comparable to the RF obtained by DB829 (14), suggesting
that both compounds are taken up primarily by the P2 trans-
porter.
In vivo mouse models with acute-stage infection with differ-
ent T. b. gambiense isolates. We assessed the efficacy of
28DAP010 in mice against four different T. b. gambiense isolates
and compared the activity with that against T. b. rhodesiense
STIB900 (Table 4). This was a crucial experiment since in vitro,
28DAP010 had been shown to be less active against the tested T. b.
gambiense isolates than against T. b. rhodesiense strain STIB900
and T. b. brucei strain BS221. However, in in vivo experiments in
mice, 28DAP010 was at least as efficacious for T. b. gambiense
strains as for T. b. rhodesiense STIB900. 28DAP010 was curative at
1  20 mg/kg i.p. and at 4  5 mg/kg i.p. in STIB900-infected mice
as well as in mice infected with either of the four T. b. gambiense
strains (ITMAP141267, STIB930, 130R, and 45R), two of which
(130R and 45R) were isolated from melarsoprol relapse patients.
At a single dose of 5 mg/kg i.p., 28DAP010 cured 3/4 STIB900-
infected mice, whereas all mice were cured of infection with the T.
b. gambiense strains ITMAP141267 and STIB930 at the identical
dose (Table 4). A group given a dose of 1  5 mg/kg i.p. was not
included in the in vivo experiments with 130R and 45R, as the high
efficacy with a 100% cure rate at a single dose of 20 mg/kg i.p. had
not been expected prior to the experiment.
Time course of drug action in vitro. The time course of drug
action of 28DAP010 in vitro versus the T. b. rhodesiense strain
STIB900 and the two T. b. gambiense strains STIB930 and
ITMAP141267 was recorded using isothermal microcalorimetry.
Drug action was studied at different drug concentrations in 10-
fold dilution steps ranging from 2 to 20,000 nM concentrations
against the T. b. rhodesiense strain STIB900 or from 20 to 20,000
nM against the two T. b. gambiense strains. Four parameters were
FIG 2 In vitro activities of pentamidine versus 28DAP010 against different T.
b. gambiense strains. Symbols represent the average IC50 of at least three inde-
pendent determinations. The first number in each set of parentheses repre-
sents the IC50 for pentamidine and the second number that for 28DAP010. No
significant correlation was observed between pentamidine and 28DAP010 ac-
tivities (r2 
 0.019).




No. of mice cured/no. infected
T. b. rhodesiense STIB900
(in vitro IC50 [nM], 17 	 4)
T. b. gambiense
ITMAP141267 (in vitro
IC50 [nM], 45 	 6)
STIB930 (in vitro IC50
[nM], 215 	 56)
130R (in vitro IC50
[nM], 71 	 33)
45R (in vitro IC50
[nM], 195 	 50)
1  5 i.p. 3/4 4/4 3/3 ND ND
1  20 i.p. 4/4 3/3 4/4 4/4 4/4
4  5 i.p. 4/4 4/4 4/4 4/4 4/4
a IC50s are expressed as means 	 standard deviations. No. of doses  mg/kg, one daily dose administered on consecutive days; ND, not determined.
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calculated from the curves for heat flow over time to describe the
time course of drug action quantitatively: (i) the onset of drug
action, (ii) the time to peak, (iii) the time to kill, and (iv) the




The time of drug action of 28DAP010 was concentration de-
pendent (Fig. 3). The higher the concentration, the faster
28DAP010 acted and killed the parasites (in contrast to DB829,
with which saturation was observed at 2,000 nM [23]). The
onset of drug action on T. b. rhodesiense strain STIB900 ranged
from 4 to 16 h, and the time to kill the parasite culture ranged
from 24 to 92 h at concentrations of 20,000 to 20 nM (Table 5). At
the highest tested drug concentration of 20,000 nM, drug action
was so strong that not all parameters could be calculated. Also, the
inhibition of the growth rate () was dependent on the drug con-
centration, ranging from 7% at 2 nM up to 93% at the highest
tested concentration of 20,000 nM.
Drug action of 28DAP010 in vitro was slower for T. b. gam-
biense strains ITMAP141267 and STIB930 (Fig. 3; Table 5) than
for T. b. rhodesiense strain STIB900. This is consistent with the
reduced activity (higher IC50s) of 28DAP010 observed for T. b.
gambiense in the alamarBlue assay. Growth of the two T. b. gam-
biense strains was also slightly slower in drug-free control cultures
( 
 0.018 to 0.024 h1, time to peak 
 53 to 58 h, and time to
overgrowth 
 144 to 172 h) than that of T. b. rhodesiense strain
STIB900 ( 
 0.029 h1, time to peak 
 34 h, and time to over-
growth 
 111 h) at identical trypanosome inocula of 5  104
trypanosomes/ml (Table 5). The onset of drug action for the two
T. b. gambiense strains ranged from 5 to 30 h and the time to kill
ranged from 46 to 126 h (2 to 5 days) at effective concentrations of
200 to 20,000 nM 28DAP010. Also, the inhibition of the growth
rate () was dependent on the drug concentration, ranging from
0.6 to 4% at 20 nM up to 82% at 20,000 nM for both T. b.
gambiense strains (Table 5).
An inoculum effect is a phenomenon that has previously been
observed with several diamidines. We studied the effect of two
FIG 3 Microcalorimetry heat flow profiles of T. b. rhodesiense strain STIB900 (A) and T. b. gambiense strains STIB930 (B) and ITMAP141267 (C) in the presence
of various concentrations of 28DAP010. Drug-free samples included parasites (5  104/ml inoculum) without drug treatment, and trypanosome-free experi-
ment did not include any parasites or drug. Each curve represents the mean of three samples.
TABLE 5 Drug action analysis of 28DAP010 by isothermal microcalorimetry







Growth rate (), mean
(SD) (h1/1,000) Inhibition (%)d
STIB900 None (drug free) 34 (4) 111 (10) 29 (1)
2a NMe 32 (8) 113 (7) 27 (1) 7
20a 16 (3) 30 (7) 92 (5) 22 (2) 24
200 7 (1) 10 (2) 49 (17) 7 (4) 76
2,000 5b 10 (1) 32 (10) 3 (2) 90
20,000b 4b 9b 24 (7) 2b 93
STIB930 None (drug free) 53 (2) 144 (8) 24 (2)
20a NM 53 (2) 146 (5) 24 (1) 0.6
200 30 (9) 50 (1) 126 (8) 23 (1) 4
2,000 9 (2) 36 (3) 90 (8) 11 (2) 52
20,000b 5b 13 (5) 46 (9) 4b 82
ITMAP141267 None (drug free) 58 (4) 172 (11) 18 (3)
20a NM 57 (4) 172 (7) 17 (3) 4
200 21 (6) 47 (3) 124 (12) 16 (3) 11
2,000 11 (4) 18 (6) 79 (7) 8 (1) 55
20,000 6 (1) 10 (1) 47 (19) 3 (1) 85
a Inhibition is too small to recover parameters from every experiment performed accurately.
b Inhibition is too strong to recover parameters from every experiment performed accurately.
c Initial inoculum density was 5  104 trypanosomes/ml.
d Inhibition was determined as follows: (1  drug/drug free)  100.
e NM, not measurable.
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different initial parasite densities (5  104/ml and 1  104/ml) on
the sensitivity to 28DAP010 by isothermal microcalorimetry (see
Fig. S1 in the supplemental material). With an inoculum of 5 
104/ml, the growth rate of T. b. rhodesiense strain STIB900 was
inhibited by 19% at 20 nM and 81% at 200 nM (Table 6). Consid-
erably stronger inhibition was observed at the lower inoculum of
1  104/ml. The parasite culture was inhibited by 85% at 20 nM
and 98% at 200 nM (Table 6; see also Fig. S1). In contrast, onset
of drug action and time to peak of the heat flow curves remained
similar with the different inocula (Table 6). The same phenome-
non was observed in the experiments with T. b. gambiense strain
STIB930. With an initial inoculum of 5  104/ml, parasite growth
rate was inhibited by 6% at a drug concentration of 200 nM and by
58% at 2,000 nM. Stronger inhibitions were observed at the lower
inoculum, with 51% at 200 nM and 93% at 2,000 nM (Table 6).
The other two parameters, onset of action and time to peak of the
heat flow curves, remained again similar at the different inocula.
No clear inoculum effect was observed at 2 nM 28DAP010 (see
Fig. S1).
Diamidines are normally taken up rapidly into trypanosomes,
but parasite death is usually delayed. We tested whether continu-
ous drug exposure is required for 28DAP010 to kill the trypano-
somes or if an exposure of 24 h is sufficient to kill the parasites at
a later time point. Inhibition of trypanosome cultures that were
incubated for 24 h with 28DAP010 and then washed was moni-
tored in drug-free culture medium by microcalorimetric analysis.
The heat flow of preexposed trypanosome samples in drug-free
culture medium was compared with that of parasites continuously
exposed to the drug. The wash-out experiments were performed
with two strains (STIB900 and STIB930).
The time to peak of the washed, drug-free samples was delayed
by 14 to 17 h compared to the drug-free samples that were not
washed (Table 6; see also Fig. S2 in the supplemental material).
This delay was attributed to loss of some trypanosomes during the
washing steps since both samples were set up and run simultane-
ously. The trypanosome culture was still alive, as seen by heat flow
rate above baseline at the 24-h time point, and heat production
did increase in the wash-out samples after any drug was removed.
This indicates that the cells were still multiplying after the drug
preexposure at a 200 or 2,000 nM concentration. However, the
cultures in the drug-free medium did die after some time (see Fig.
S2). The times to kill after drug wash-out were delayed compared
to those with continuous drug exposure (82 versus 37 h) for T. b.
rhodesiense strain STIB900 at 200 nM and for T. b. gambiense
strain STIB930 (130 versus 85 h) at 2,000 nM (Table 6). However,
the 24-h exposure was sufficient to kill STIB900 at 200 nM and
STIB930 at 2,000 nM at the later time, which confirms that lethal
concentrations were taken up within the first 24 h. With lower
drug concentrations, a revival of the parasite culture after wash-
out was observed in some cases: with STIB900 at 20 nM and with
STIB930 at 200 nM (data not shown).
Pharmacokinetics and brain exposure of 28DAP010 after i.v.
and i.p. administration in mice. The mean plasma concentra-
tion-time profiles of 28DAP010 were determined after a single i.v.
dose of 7.5 mol/kg (2.4 mg/kg) or a single i.p. dose of 65 mol/kg
(21 mg/kg) (Fig. 4). Both profiles exhibited at least a biphasic
decline with an initial distribution phase and a terminal elimina-
tion phase. Pharmacokinetic outcomes were determined using
noncompartmental analysis (Table 7). Following i.v. administra-
tion, the average plasma concentration of 28DAP010 reached
70.2 M about 1 min after i.v. administration, but it quickly de-
creased, to below 1 M by 2 h postdose and below 0.1 M by 8 h
postdose (Fig. 4A). The steady-state volume of distribution was 15
liters/kg, markedly greater than the physiologic fluid volume. The
TABLE 6 Effects of inoculum and drug wash-out on drug action of 28DAP010 by isothermal microcalorimetry







Growth rate (), mean
(SD) (1,000) (h1) Inhibitione (%)
STIB900
5  104/ml None (drug free) 38 (3) 118 (7) 27 (2)
20 14 (2) 33 (1) 93 (4) 22 (2) 19
200 6 (1) 12 (1) 37 (3) 5 (1) 81
1  104/ml (low inoculum) None (drug free) 50 (3) 125 (5) 27 (1)
20 12 (7) 29 (2) 59 (2) 4 (1) 85
200b 9b 13b 25b NMa,b 98
5  104/ml, wash-out None (drug free) 55 (4) 132 (11) 26 (2)
200 30 45 (7) 82 (19) 6 (2) 77
STIB930
5  104/ml None (drug free) 50 (2) 148 (9) 24 (2)
200 26 (4) 50 (1) 121 (8) 23 (1) 6
2,000 8 (2) 36 (3) 85 (7) 10 (2) 58
1  104/ml (low inoculum) None (drug free) 68 (1) 160 (10) 24 (2)
200 27 (3) 52 (5) 100 (11) 12 (2) 51
2,000b 15b 31 (5) 60 (3) 2b 93
5  104/ml, wash-out None (drug free) 64 (5) 154 (11) 21 (1)
200c 30 61 (2) 128 (9) 21 (1) 0
2,000d 30 60 (4) 130 (12) 15 (2) 28
a NM, not measurable.
b Inhibition is too strong to recover parameters from every experiment performed accurately.
c Only two independent experiments were performed (in triplicate).
d Only one independent experiment was performed (in triplicate).
e Inhibition was determined as follows: (1  drug/drug free)  100.
Wenzler et al.
4458 aac.asm.org Antimicrobial Agents and Chemotherapy
 on D
ecem









average brain concentration of 28DAP010 was 4.2 M at 72 h
postdose, approximately 190-fold higher than the corresponding
plasma concentration (Table 7). Following i.p. administration,
28DAP010 was rapidly absorbed into blood circulation, reaching
a plasma Cmax of 69.6 M at 15 min postdose. The average plasma
concentration of 28DAP010 decreased below 1 M by 8 h post-
dose but remained above 0.1 M for at least 72 h after injection
(Fig. 4B). The average brain concentration of 28DAP010 was 9.3
M at 72 h postdose, approximately 69-fold higher than the cor-
responding plasma concentration (Table 7).
The nonspecific binding of 28DAP010 to mouse plasma pro-
teins and brain tissues was determined (Table 7). 28DAP010
showed moderate binding to mouse plasma (fu, plasma 
 26.3%)
but bound avidly to brain tissues (fu, brain 
 0.69%).
Time of drug action in vivo. The time of drug action of
28DAP010 in vivo was determined following a single i.p. dose of 20
mg/kg to mice infected with T. b. rhodesiense strain STIB900 or the
T. b. gambiense strains ITMAP141267 and STIB930. The in vivo
time to kill (parasite clearance time) of 28DAP010 was determined
in the same experiment as the previously reported data for DB829
(23). Typically, diamidines are rather slow-acting compounds, es-
pecially DB829. Therefore, the first blood sample collected was 24
h after treatment. This time point is close to the parasite clearance
time of 28DAP010, as in each group one mouse (STIB930 and
ITMAP141267) or three of four mice (STIB900 infected) were
already parasite free 24 h after drug administration.
The parasite clearance time was, on average, 26 h (24 to 32 h)
when mice were infected with the T. b. rhodesiense strain STIB900
(Table 8). This is in the range of the in vitro time to kill at 2,000 to
20,000 nM concentrations (24 to 32 h [Table 5]). The time to kill
for the T. b. gambiense strain ITMAP141267 was, on average, 42 h
(24 to 56 h); that in STIB930-infected mice was 40 h (24 to 48 h)
(Table 8), which is slightly faster than the in vitro time to kill at the
two highest concentrations of 2,000 and 20,000 nM (Table 4).
DISCUSSION
Our studies of the diamidine 28DAP010 and its two analogues
27DAP060 and 19DAP025 showed that they are highly active
against African trypanosomes in vivo. In the STIB900 acute-stage
mouse model, the mice were cured by a single i.p. dose (Table 2)
(20). However, among the three analogues, only 28DAP010 cured
mice with second-stage infections in the GVR35 CNS mouse
model (Table 3).
The availability of more efficacy data for a number of diami-
FIG 4 Plasma (filled circles) and brain (open squares) concentration-time profiles of 28DAP010 following intravenous (A) and intraperitoneal (B) adminis-
tration to uninfected mice. The doses were 7.5 mol/kg (or 2.4 mg/kg) for i.v. administration and 65 mol/kg (or 21 mg/kg) for i.p. administration. Symbols and
error bars represent means and standard errors of triplicate determinations, respectively.
TABLE 7 Pharmacokinetic parameters of 28DAP010 after i.v. and i.p.
administration to uninfected mice
Compartment Parametera




7.5 (2.4) 65 (21)




Tmax, h NC 0.25
AUC0-, mol/liter · h 15 102
t1/2, h 68 26
CL, liter/h/kg 0.50 NC
Vss, liters/kg 15 NC
MRT, h 30 NC
fu, plasma, % 26.3 	 2.2
b
Brain Cbrain_72h, mol/liter 4.2 	 4.5




B/P at 72 h 190 69
fu, brain, % 0.69 	 0.07
b
a C5 min, plasma concentration at 5 min postdose; Cmax, maximum plasma
concentration; Tmax, time to reach Cmax; AUC0-, area under the plasma
concentration-time curve from time zero to infinitity; t½, terminal elimination half-life;
CL, clearance; Vss, steady-state volume of distribution; MRT, mean residence time;
Cbrain_72h, brain concentration at 72 h postdose; AUCbrain_0 –72h, area under the brain
concentration-time curve from time zero to 72 h postdose; B/P, brain-to-plasma
concentration ratio; fu, drug unbound fraction; C5 min, plasma concentration at 5 min
postdose; B/P, brain-to-plasma concentration ratio.
b Mean 	 standard deviation of triplicate determinations.
c NC, not calculated.
d Plasma concentration at 1 min postdose.
TABLE 8 In vivo time to kill (parasite clearance time) in infected mice
after 28DAP010 treatment




a 28DAP010 was given as a single dose at 20 mg/kg i.p. 3 days after infection. Values are
means of four mice per group; ranges represents the time when the first and last mouse
became aparasitemic.
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dines makes it possible to consider some structure-activity re-
lationships. 28DAP010 is chemically closely related to DB829
(Fig. 1). In the present study, 19DAP025 was less CNS potent and
more toxic than its diaza analogue 28DAP010 (Table 3). Most of
the infected mice died during or shortly after treatment with
19DAP025 at 5  25 mg/kg or 10  20 mg/kg i.p. A similar com-
parison can be made between furamidine and DB829 (14).
27DAP060, a regioisomer of 28DAP010, was highly active in vivo
in the acute-stage mouse model (Table 2) but less CNS active than
28DAP010 (Table 3). This has been observed in previous experi-
ments with aza analogues of furamidine (DB75) (24), in which
only DB829 cured CNS-infected mice (14). The two pyridyl nitro-
gen atoms introduced in DB75 decreased the pKa value of DB829
by only 1 unit, and it was still above physiological pH (36). The
higher BBB penetration can therefore not be attributed to an effect
on pKa alone. The identical positions of the nitrogen atoms in the
outer pyridine rings in both DB829 and 28DAP010 (Fig. 1) may
play a crucial role in CNS potency and in the recognition of the
molecules by a presumed transporter protein located at the BBB,
which supports the penetration of 28DAP010 and DB829 into the
brain. The CNS mouse model results for these two molecules con-
firm that certain diamidines do indeed have potential for curing
not only first-stage but also second-stage HAT by the parenteral
administration route.
There is still some interest in the use of prodrugs, particularly
because of their potential for oral administration. Since the ana-
logue DB868, the methamidoxime prodrug of DB829, cured mice
showing CNS infection after oral administration (14), we ana-
lyzed the potency of DB1244, which is a methamidoxime prodrug
of 28DAP010, in the GVR35 CNS mouse model at the same dos-
age. However, DB1244 was much less CNS active than DB868
(Table 3) (14), although its acute-stage mouse model activity was
similar (Table 2) (14, 20). Further metabolism and pharmacoki-
netic studies of DB1244 are needed to explain the observed effi-
cacy difference. When DB868 was tested by the oral route in vervet
monkeys with second-stage infections, the therapeutic window
was smaller for the prodrug DB868 than for its active diamidine
DB829 (18). Measurement of the efficacy of 28DAP010 in the
second-stage vervet monkey model will be needed for comparison
with DB829.
Our greatest concern was to test the susceptibilities of different
T. b. gambiense isolates to 28DAP010, as 98% of all HAT cases
are due T. b. gambiense infections (2). Most of our strains were
isolated from patients from the Democratic Republic of the
Congo (DRC), the country harboring most HAT patients (1). We
observed considerable reduction in the in vitro activity of
28DAP010 against the different T. b. gambiense strains compared
to T. b. rhodesiense and T. b. brucei strains. This phenomenon has
been observed previously with DB829 (against all tested T. b. gam-
biense isolates) and with pentamidine against recent isolates
(K03048, 40R, 45R, 130R, and 349R) that were derived from pa-
tients within the last 10 years (23). However, our in vivo experi-
ments with T. b. gambiense infections with four different isolates
(ITMAP141267, STIB930, 130R, and 45R) were encouraging.
28DAP010 proved to be highly active against T. b. gambiense as
well as T. b. rhodesiense isolates. The T. b. gambiense-infected mice
were cured at doses comparable to, or even lower than, those used
for mice infected with T. b. rhodesiense STIB900 (Table 4). The
reduced in vitro activities of 28DAP010 and DB829 may be the
result of factors that do not influence activity in vivo. They could
be due to the slower growth of T. b. gambiense isolates or be the
result of different culture conditions leading, for example, to a
downregulation of a diamidine uptake transporter(s) (37) and
thus to a reduced susceptibility of the T. b. gambiense isolates in
vitro (23).
Cross-resistance between pentamidine and melamine-based
arsenicals such as melarsoprol is a well-known phenomenon (38–
40) involving the P2 transporter (41, 42). Therefore, we were con-
cerned about a possible cross-resistance between 28DAP010 and
these drugs or the possible development of more resistant trypano-
some strains. Tests using a P2 knockout (KO) T. brucei strain indi-
cated that the uptake of 28DAP010 is dependent on the P2 trans-
porter. We observed a resistance factor (IC50 P2-KO/IC50 wild type) of
16, which was similar to that for DB829 and diminazene in the
72-h alamarBlue assay (14). Recently another transporter, aqua-
porin 2 (AQP2), was identified which is also involved in drug
uptake and the development of resistance to pentamidine and
melarsoprol (40, 43, 44). However, cross-resistance seems to be
limited to the two diamidines pentamidine and 28DAP010, as the
IC50s of the two diamidines for different T. b. gambiense field
isolates do not correlate (r2 
 0.019) (Fig. 2). A similar effect was
observed between pentamidine and diminazene (44). Analysis of
T. b. gambiense field isolates with reduced susceptibility to pent-
amidine did reveal rearrangements of the TbAQP2/TbAQP3 locus
accompanied by TbAQP2 gene loss (44). The mutant T. b. gam-
biense field isolates were less susceptible to pentamidine and me-
larsoprol but still susceptible to diminazene (44) and DB829 (23)
and, as can be seen in Fig. 2, also to 28DAP010. Additionally,
28DAP010 was able to cure mice that were infected with recent T.
b. gambiense isolates that were less susceptible to pentamidine
in vitro (Table 4). Lack of AQP2 dependency for uptake of
28DAP010 and DB829 would explain why the recent T. b. gam-
biense isolates that were less susceptible to pentamidine were still
sensitive to 28DAP010 and DB829.
An understanding of the pharmacokinetics and pharmacody-
namics of drugs is necessary to develop effective treatment sched-
ules. The time of drug action on trypanosomes can be determined
in vitro using isothermal microcalorimetry (21). This method is
based on the heat production of metabolically active parasites and
thus allows studying the growth of cultures in the presence and
absence of drugs (21, 23). It is simple to use and offers constant
monitoring of a parasite population on a real-time basis (21).We
analyzed the time of drug action of 28DAP010 at different con-
centrations on 3 different trypanosome strains. The time course of
drug action was concentration dependent. No saturation could be
observed with 28DAP010, whereas in experiments with DB829,
saturation was found above 2,000 nM (23). This was probably due
to saturation of the P2 transporter with DB829 (23, 37). It is pos-
sible that 28DAP010 is taken up by an additional high-capacity,
low-affinity transporter at high drug concentrations, leading to a
stronger drug action at concentrations above 2,000 nM.
We studied the inoculum effect of 28DAP010 by using identi-
cal drug concentrations but different initial parasite densities (in-
ocula), 1  104/ml and 5  104/ml (see Fig. S1 in the supplemental
material). We observed a strong inoculum effect on the growth
rate () and on the time to kill. However, the onset of drug action
and the time to peak were less affected at the different trypano-
some starting densities at identical drug concentrations, as can be
observed at 20 and 200 nM concentrations with STIB900 or at 200
and 2,000 nM concentrations with STIB930 (Table 6). This indi-
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cates that the drug action starts almost concurrently at the differ-
ent starting densities using the same drug concentration. This
phenomenon has been previously observed with DB829 and pen-
tamidine in microcalorimetric studies (23). The major reason for
the inoculum effect in vitro seems to be the concurrent onset of
drug action, which appears at a much lower trypanosome density
at the lower inoculum. Therefore, the inhibition of these com-
pounds is more pronounced than for the drug-free control sam-
ples at the lower inoculum than at the higher inoculum.
The time taken to kill parasites is an important parameter to
measure treatment efficacy. It has been shown that several diami-
dines (such as pentamidine, DB75, and DB829) are rapidly taken
up by African trypanosomes; however, trypanosome death oc-
curred much later (9, 23, 45, 46). We studied the drug action at
effective concentrations (200 nM for STIB900 and 2,000 nM for
STIB930) for an exposure time of 24 h, after which the drug was
washed out (see Fig. S2 in the supplemental material). Growth was
followed by isothermal microcalorimetry. After the drug had been
washed out from the trypanosome culture, the parasites seemed to
grow for at least one more day (see time to peak in Table 6). The
trypanosomes were finally killed as a consequence of the 24-h drug
exposure, but death occurred almost 2 days later than in contin-
uously exposed trypanosomes (Table 6; see also Fig. S2). Micro-
calorimetric studies with multiple concentrations of 28DAP010
and multiple time points would be needed to examine this phe-
nomenon in detail, but this was beyond the scope of this study.
The performed wash-out experiments suggest that the high max-
imum drug concentration in plasma (Cmax) after i.p. administra-
tion (Table 7) resulted in the high in vivo efficacy observed after a
single i.p. dose with 28DAP010. The great in vivo efficacy in T. b.
rhodesiense- and T. b. gambiense-infected mice (Tables 2 and 4) is
not surprising considering the high Cmax combined with the long
half-life of 28DAP010.
28DAP010 showed a high brain-to-plasma concentration
(B/P) ratio at 72 h postdose (Table 7), suggesting good CNS pen-
etration. The high B/P ratio appears to be largely driven by the
more extensive binding of 28DAP010 to brain tissue than to
plasma (fu, plasma/fu, brain). However, it has been previously ob-
served using fluorescence microscopy that DB75 did not distrib-
ute into brain parenchyma but sequestered within endothelial
cells lining the BBB and blood-cerebrospinal fluid barrier. It is
unknown whether 28DAP010 was also sequestered within the en-
dothelial cells or distributed more extensively into brain paren-
chyma. Nonetheless, the observed high B/P ratio and efficacy in
the CNS T. b. brucei mouse model support 28DAP010 as a CNS-
active trypanocide.
The speed at which drugs act is of varying clinical importance.
Fast elimination of the parasite is not as vital for HAT patients as it
is for patients infected with some other parasites, like malaria par-
asites, which cause much more rapid death. However, fast-acting
drugs are of advantage to minimize the risk of resistant parasite
selection in the patient and to reduce the hospitalization time. In
vitro as well as in vivo, 28DAP010 was faster acting than DB829.
However, a short exposure to 28DAP010 or to DB829 (23) was
sufficient to kill the trypanosomes in a delayed manner (Table 6).
High drug levels therefore do not need to be maintained over the
entire parasite clearance time in vivo.
More problematic than a relatively slow speed of action are
undesirable side effects such as hepatotoxicity or nephrotoxicity.
Such effects have been observed for pentamidine (47) and DB289
(pafuramidine) (15, 16, 48), and the nephrotoxicity of pafurami-
dine actually led to the termination of the clinical studies (16). It is
encouraging that studies with rats and mice indicate that nephro-
toxicity is not clearly class related (49). DB829 (resulting from
DB868 administration) accumulated less in liver and kidneys than
did DB75 (after pafuramidine administration) (16). The toxicity
profile of 28DAP010 may also differ from that observed for pa-
furamidine.
Second-stage efficacy of DB829 has been demonstrated in the
mouse (14) and monkey (18) models. In the present study,
28DAP010 revealed similar efficacies in mouse models. Both mol-
ecules are able to cure both disease stages and infections with both
studied subspecies, T. b. gambiense and T. b. rhodesiense, at low
and tolerated doses. Extensive toxicity studies of 28DAP010 and
DB829 side by side are still needed. Drug tolerability will be an
important criterion for choosing the better of these two diami-
dines for further drug development.
There is a continuing discussion about the relative advantages
and disadvantages of prodrugs and intrinsically active com-
pounds. The use of an orally active prodrug to cure second-stage
HAT could be helpful in resource-poor settings. However, paren-
teral administration also has advantages. The use of an active di-
amidine will simplify the pharmacokinetic and toxicity analyses
that will be needed if the drug is to be used, and treatment with one
of the backup compounds, 28DAP010 or DB829, could be short
and simple. Treatment duration of 5 days or less for second stage
could well be feasible and could be tested for further development
for HAT on the basis of the favorable pharmacokinetics after par-
enteral administration.
A sustained drug development pipeline will increase the
chance of getting a new and improved treatment into the market
(19). This will help to control, and eventually to eliminate, the
disease (50, 51). With 28DAP010, we have found a new promising
backup diamidine as a preclinical candidate for the treatment of
first- and second-stage African sleeping sickness.
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